It has been the eighth year since I returned to Hunan from studying in the US to establish Huateng Pharma. Since its foundation, Huateng Pharma has maintained a steady and high growth rate. On behalf of all our staff, I would like to express our sincere gratitude to our customers at home and abroad for your great support.
As a high-tech enterprise, Huateng Pharma has continuously increased its efforts on drug research and development. We have established a 5000 square meters R&D center in Changsha and set up Huateng Drug Research Institute. We have also invested 300 million RMB to build a 34,000 square meter industrial park in Wangcheng District, Changsha, with an annual capacity of over 1 billion RMB.
At present, Huateng Pharmaceutical has developed thousands of high-end biopharmaceutical products and applied for more than 300 invention patents.
Huateng Pharma has introduced Series A and Series B financing in 2019 and 2021, respectively. We strive to quickly complete the IPO and develop into a first-class pharmaceutical company with a capacity of 10 billion. We will do our best to make outstanding contributions to the development of human medicine and health together!
CEO, Zeping Deng, Ph. D.